MAPT and Alzheimer disease: The binding of Tau antibodies A–F was also assessed by immunohistochemistry using cortical sections obtained from both AD patients (where Tau pathology was confirmed by AT8 positive immunostaining) and healthy control brains (where no AT8 immunostaining could be detected).